Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer Aug 9, 2022
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital Aug 3, 2022
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference Jun 21, 2022
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma Jun 15, 2022
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma May 27, 2022
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update May 13, 2022
Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Apr 14, 2022
